Dr Shoemaker's scientific background is in pharmacology and toxicology with a focus on neurodegenerative diseases, endocrine disorders and gastroenterology. For her PhD, she investigated and published on the involvement of the second cannabinoid receptor (CB2) in the pathology of amyotrophic lateral sclerosis. For her post-doctoral fellowship at Emory University, she studied the pathophysiology of enteric axons during the early stages of diabetes. Dr Shoemaker is an experienced editor and began working for the Edanz Group in early 2009.